(HealthDay)—Evidence is mounting that a marijuana-derived oil might benefit some children with epilepsy whose seizures aren't controlled by approved medications, two new studies show.
Dec 8, 2015
0
23
Treatment with cannabidiol reduces some major symptoms in mice with a genetic condition recapitulating Dravet syndrome, a devastating childhood brain disorder.
Oct 10, 2017
0
116
An extract from the plant Cannabis sativa (trade name Sativex) was approved in May 2011 for patients suffering from moderate to severe spastic paralysis and muscle spasms due to multiple sclerosis (MS). In an early benefit ...
Sep 17, 2012
0
0
Commercial antidepressants typically take two to four weeks to have a significant effect on a depressed patient. They are also ineffective in approximately 40 percent of cases. Finding new, fast-acting drugs for depression ...
Aug 31, 2018
0
17
Taking cannabidiol may cut seizures in half for some children and adults with Lennox-Gastaut syndrome (LGS), a severe form of epilepsy, according to new information released today from a large scale controlled clinical study ...
Apr 18, 2017
0
11
A new British Journal of Clinical Pharmacology review examines the potential of medicinal cannabis—or medical marijuana—for helping patients with intractable epilepsy, in which seizures fail to come under control with ...
Aug 8, 2018
0
0
Cannabidiol may be effective in halving the severity of symptoms and impairment caused by chronic anxiety, a pilot study by Orygen, Australia's center of excellence in youth mental health, has shown.
Aug 3, 2022
0
19
For adults with drug-resistant focal epilepsy, no difference in efficacy was observed at 12 weeks for adjunctive therapy with transdermal cannabidiol versus placebo, according to a study published online July 8 in JAMA Network ...
Jul 18, 2022
0
11
Brazil on Wednesday for the first time approved the use of a marijuana derivative to treat people suffering from severe seizures and other conditions.
Jan 14, 2015
0
4
There is no strong evidence to back the use of cannabis extract in the treatment of Multiple Sclerosis (MS), concludes a review of the available evidence on the first licensed preparation, published in the December issue ...
Dec 12, 2012
0
0
